DIMABiotechnology provides pre-designed and validated antibody molecules to support early-stage drug discovery programs. Its portfolio includes more than 5,000 ready-to-use lead antibodies targeting around 400 therapeutic targets, each supplied with verified sequences and supporting validation data.
